title: Effects of lung ventilation-perfusion and muscle metabolism-perfusion heterogeneities on maximal O2 transport and utilization.
abstract: CONCLUSIONS
  We expanded a prior model of whole-body O2 transport and utilization based on diffusive O2 exchange in the lungs and tissues to additionally allow for both lung ventilation-perfusion and tissue metabolism-perfusion heterogeneities, in order to estimate V̇O2 and mitochondrial PO2 (PmO2) during maximal exercise. Simulations were performed using data from (a) healthy fit subjects exercising at sea level and at altitudes up to the equivalent of Mount Everest and (b) patients with mild and severe chronic obstructive pulmonary disease (COPD) exercising at sea level. Heterogeneity in skeletal muscle may affect maximal O2 availability more than heterogeneity in lung, especially if mitochondrial metabolic capacity (V̇ MAX ) is only slightly higher than the potential to deliver O2 , but when V̇ MAX is substantially higher than O2 delivery, the effect of muscle heterogeneity is comparable to that of lung heterogeneity. Skeletal muscle heterogeneity may result in a wide range of potential mitochondrial PO 2 values, a range that becomes narrower as V̇ MAX increases; in regions with a low ratio of metabolic capacity to blood flow, PmO2 can exceed that of mixed muscle venous blood. The combined effects of lung and peripheral heterogeneities on the resistance to O2 flow in health decreases with altitude.
  Previous models of O2 transport and utilization in health considered diffusive exchange of O2 in lung and muscle, but, reasonably, neglected functional heterogeneities in these tissues. However, in disease, disregarding such heterogeneities would not be justified. Here, pulmonary ventilation-perfusion and skeletal muscle metabolism-perfusion mismatching were added to a prior model of only diffusive exchange. Previously ignored O2 exchange in non-exercising tissues was also included. We simulated maximal exercise in (a) healthy subjects at sea level and altitude, and (b) COPD patients at sea level, to assess the separate and combined effects of pulmonary and peripheral functional heterogeneities on overall muscle O2 uptake (V̇O2) and on mitochondrial PO2 (PmO2). In healthy subjects at maximal exercise, the combined effects of pulmonary and peripheral heterogeneities reduced arterial PO2 (PaO2) at sea level by 32 mmHg, but muscle V̇O2 by only 122 ml min(-1) (-3.5%). At the altitude of Mt Everest, lung and tissue heterogeneity together reduced PaO2 by less than 1 mmHg and V̇O2 by 32 ml min(-1) (-2.4%). Skeletal muscle heterogeneity led to a wide range of potential PmO2 among muscle regions, a range that becomes narrower asV̇ MAX increases, and in regions with a low ratio of metabolic capacity to blood flow, PmO2 can exceed that of mixed muscle venous blood. For patients with severe COPD, peak V̇O2 was insensitive to substantial changes in the mitochondrial characteristics for O2 consumption or the extent of muscle heterogeneity. This integrative computational model of O2 transport and utilization offers the potential for estimating profiles of PmO2 both in health and in diseases such as COPD if the extent for both lung ventilation-perfusion and tissue metabolism-perfusion heterogeneity is known.
authors: Hospital Clinic, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Catalunya, Spain; Centro de Investigación en Red de Enfermedades Respiratorias (CibeRes), Palma de Mallorca, Spain.
authors: I
authors: I
authors: Cano
authors: J
authors: J
authors: Roca
authors: P D
authors: PD
authors: Wagner
mesh_terms: D000531:Altitude; D015444:Exercise / Q000502:physiology*; D006801:Humans; D000860:Hypoxia / Q000378:metabolism / Q000503:physiopathology*; D008168:Lung / Q000378:metabolism; D008954:Models, Biological; D018482:Muscle, Skeletal / Q000378:metabolism*; D010101:Oxygen Consumption / Q000502:physiology*; D029424:Pulmonary Disease, Chronic Obstructive / Q000378:metabolism / Q000503:physiopathology; D012123:Pulmonary Ventilation / Q000502:physiology*
references: N Engl J Med. 1971 Jun 3;284(22):1232-6
references: 5573833
references: J Clin Invest. 1974 Jul;54(1):54-68
references: 4601004
references: Am J Physiol. 1977 Nov;233(5):C135-40
references: 200145
references: Med Sci Sports Exerc. 1982;14(4):253-62
references: 6752626
references: J Physiol. 1985 Sep;366:233-49
references: 4057091
references: Circ Res. 1987 Jan;60(1):1-13
references: 3552283
references: Respir Physiol. 1987 Aug;69(2):129-47
references: 3114851
references: Am Rev Respir Dis. 1987 Sep;136(3):605-12
references: 3631733
references: J Appl Physiol (1985). 1987 Dec;63(6):2348-59
references: 3436869
references: J Appl Physiol (1985). 1988 Apr;64(4):1309-21
references: 3132445
references: Microvasc Res. 1988 Sep;36(2):162-71
references: 3185308
references: Scand J Med Sci Sports. 2000 Dec;10(6):346-50
references: 11085562
references: J Appl Physiol (1985). 2001 Oct;91(4):1845-53
references: 11568171
references: J Appl Physiol (1985). 2001 Nov;91(5):2255-65
references: 11641369
references: J Appl Physiol. 1966 Jul;21(4):1375-6
references: 5916678
references: Respir Physiol. 1969 Jun;7(1):88-110
references: 5809098
references: J Appl Physiol (1985). 1992 Sep;73(3):1114-21
references: 1400024
references: Respir Physiol. 1993 Aug;93(2):221-37
references: 8210760
references: Respir Physiol. 1996 Dec;106(3):329-43
references: 9017851
references: J Exp Biol. 1998 Apr;201(Pt 8):1129-39
references: 9510525
references: Chest. 2005 Aug;128(2):787-91
references: 16100168
references: Intensive Care Med. 2008 Jun;34(6):994-1001
references: 18421437
references: Am J Respir Crit Care Med. 2010 Feb 1;181(3):270-8
references: 19875684
references: Adv Exp Med Biol. 2010;662:7-25
references: 20204766
references: N Engl J Med. 2011 Aug 11;365(6):537-47
references: 21830968
references: Anesth Analg. 2013 Oct;117(4):834-46
references: 23592604
references: Respir Physiol Neurobiol. 2013 Dec 1;189(3):477-83
references: 24012990
references: J Appl Physiol (1985). 2015 Mar 15;118(6):783-93
references: 25593285